Argenica Therapeutics - AGN (ASX) News & Expert Insights from Stockhead

Argenica Therapeutics Limited (ASX:AGN) is a Perth-based biotechnology company developing a groundbreaking neuroprotective treatment known as ARG-007. The company’s mission is to improve outcomes for patients suffering from acute neurological injuries such as stroke, traumatic brain injury, and hypoxic brain damage (e.g. from cardiac arrest).

ARG-007 is a synthetic peptide designed to protect brain cells from dying in the minutes and hours after these types of injuries. Uniquely, it is intended to be administered by first responders or emergency room staff before a patient receives hospital-based care, aiming to significantly reduce long-term disability and healthcare costs associated with brain injury.

AGN is currently undertaking a Phase 2 clinical trial in stroke patients to assess the safety and efficacy of ARG-007 in a real-world hospital setting. AGN has already completed a successful Phase 1 trial and shown strong preclinical evidence in multiple models of brain injury.

With a strong scientific foundation, an experienced leadership team – led by MD/CEO, Dr. Liz Dallimore – and growing clinical momentum, AGN presents a compelling investment opportunity based on the company’s developments in the emerging field of neuroprotection—a space where no drug has yet been approved despite the global unmet need.

KEY PEOPLE

Dr Dallimore led the company’s IPO in June 2021 and has since driven its progress from preclinical research into Phase 2 clinical trials in stroke patients.

Dr Dallimore holds a PhD in Neuroscience jointly awarded by the University of Oxford and the University of Western Australia, an MBA from AGSM, and has over 20 years of experience across biotechnology and management consulting, including senior roles at KPMG, EY, and PwC.

Angus has more than 25 years’ experience in biotechnology, agritech, medical devices and pharmaceutical sectors, and has a proven track record in guiding novel therapeutic assets through clinical validation to commercialisation for both ASX and NASDAQ listed companies.

Dianne holds a Master of Biotechnology, a Bachelor of Science (Hons), and a Graduate Diploma in Intellectual Property Law, is a registered patent and trademark attorney, and serves on multiple industry boards as well as serving on Deakin University Council.

With over 25 years leading stroke and neurotrauma research at the Perron Institute, Meloni and his team identified a novel class of cationic arginine rich peptides (CARPs), including the lead therapy ARG 007 now in Phase 2 clinical trials for ischemic stroke.

He earned his PhD from Murdoch University in 1993 and has since shaped the field through extensive preclinical and translational studies focused on understanding brain injury mechanisms and developing peptide based therapeutics.